Sporadic epithelial ovarian cancer: clinical relevance of BRCA1 inhibition in the DNA damage and repair pathway.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Journal of Clinical Oncology

• Publication date

  2008-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2007.11.3902PMID 18591560
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Brca1 heterozygous mice have shortened life span and are prone to ovarian tumorigenesis with haploinsufficiency upon ionizing irradiation

  2007cited by this paper
• Functional Characterization of a Novel BRCA1-Null Ovarian Cancer Cell Line in Response to Ionizing Radiation

  2007cited by this paper
• Epigenetic Inactivation of the Chromosomal Stability Control Genes BRCA1, BRCA2, and XRCC5 in Non–Small Cell Lung Cancer

  2007cited by this paper
• Conditional inactivation of Brca1 in the mouse ovarian surface epithelium results in an increase in preneoplastic changes.

  2007cited by this paper
• Recent advances in myelodysplastic syndromes.

  2007cited by this paper
• Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers.

  2006cited by this paper
• Mouse models of BRCA1 and BRCA2 deficiency: past lessons, current understanding and future prospects

  2006cited by this paper
• Multifactorial contributions to an acute DNA damage response by BRCA1/BARD1-containing complexes.

  2006cited by this paper
• A mouse model for the molecular characterization of brca1-associated ovarian carcinoma.

  2006cited by this paper
• Reduced BRCA1 expression due to promoter hypermethylation in therapy-related acute myeloid leukaemia

  2006cited by this paper
• Prevention of Brca1-Mediated Mammary Tumorigenesis in Mice by a Progesterone Antagonist

  2006cited by this paper
• Aspirin for the Primary Prevention of Cardiovascular Events in Women and Men: A Sex-Specific Meta-Analysis of Randomized Controlled Trials

  2006cited by this paper
• BRCA1 Downregulation Leads to Premature Inactivation of Spindle Checkpoint and Confers Paclitaxel Resistance

  2006cited by this paper
• Small Interfering RNA Screens Reveal Enhanced Cisplatin Cytotoxicity in Tumor Cells Having both BRCA Network and TP53 Disruptions

  2006cited by this paper
• PARP-1 inhibitors: are they the long-sought genetically specific drugs for BRCA1/2-associated breast cancers?

  2006cited by this paper
• BRCA1 Regulates Gene Expression for Orderly Mitotic Progression

  2005cited by this paper
• Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

  2005cited by this paper
• Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

  2005cited by this paper
• Modulation of aromatase expression by BRCA1: a possible link to tissue-specific tumor suppression

  2005cited by this paper
• The carboxyl-terminal of BRCA1 is required for subnuclear assembly of RAD51 after treatment with cisplatin but not ionizing radiation in human breast and ovarian cancer cells.

  2005cited by this paper
• High-resolution methylation analysis of the BRCA1 promoter in ovarian tumors.

  2005cited by this paper
• BRCA1 expression in a large series of sporadic ovarian carcinomas: a Gynecologic Oncology Group study

  2005cited by this paper
• Hallmarks of 'BRCAness' in sporadic cancers

  2004cited by this paper
• Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage

  2004cited by this paper
• Loss of heterozygosity (LOH) in ovarian cancer

  2004cited by this paper
• Biology of epithelial ovarian cancer: implications for screening women at high genetic risk.

  2004cited by this paper
• FISH analysis of BRCA1 copy number in paraffin-embedded ovarian cancer tissue samples.

  2004cited by this paper
• BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer.

  2004cited by this paper
• A requirement for breast-cancer-associated gene 1 (BRCA1) in the spindle checkpoint.

  2004cited by this paper
• Expression of BRCA1 protein in benign, borderline, and malignant epithelial ovarian neoplasms and its relationship to methylation and allelic loss of the BRCA1 gene

  2004cited by this paper
• DNA damage tumor suppressor genes and genomic instability.

  2004cited by this paper
• BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells

  2003cited by this paper
• JNK/SAPK Mediates Doxorubicin-Induced Differentiation and Apoptosis in MCF-7 Breast Cancer Cells

  2003cited by this paper
• Decitabine: development of a DNA methyltransferase inhibitor for hematological malignancies.

  2003cited by this paper
• Large-scale genomic instability predicts long-term outcome for women with invasive stage I ovarian cancer.

  2003cited by this paper
• Differing effects of breast cancer 1, early onset (BRCA1) and ataxia‐telangiectasia mutated (ATM) mutations on cellular responses to ionizing radiation

  2003cited by this paper
• Role of BRCA1 in cellular resistance to paclitaxel and ionizing radiation in an ovarian cancer cell line carrying a defective BRCA1

  2003cited by this paper
• Histone H2AX phosphorylation is dispensable for the initial recognition of DNA breaks

  2003cited by this paper
• Prognostic significance of BRCA1 expression in sporadic breast carcinomas

  2003cited by this paper
• Impact of germline BRCA1 mutations and overexpression of p53 on prognosis and response to treatment following breast carcinoma

  2003cited by this paper
• BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis.

  2003cited by this paper
• Improved survival in women with BRCA‐associated ovarian carcinoma

  2003cited by this paper
• BRCA1: mechanisms of inactivation and implications for management of patients.

  2002cited by this paper
• BRCA1 regulates the G2/M checkpoint by activating Chk1 kinase upon DNA damage

  2002cited by this paper
• Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers.

  2002cited by this paper
• Stable karyotypes in epithelial cancer cell lines despite high rates of ongoing structural and numerical chromosomal instability.

  2002cited by this paper
• Review Cancer Susceptibility and the Functions of BRCA1 and BRCA2

  2002cited by this paper
• Dominant-negative activity of a Brca1 truncation mutant: effects on proliferation, tumorigenicity in vivo, and chemosensitivity in a mouse ovarian cancer cell line.

  2002cited by this paper
• Cancer susceptibility and the functions of BRCA1 and BRCA2.

  2002cited by this paper
• Inactivation of BRCA1 and BRCA2 in ovarian cancer.

  2002cited by this paper
• A significant response to neoadjuvant chemotherapy in BRCA1/2 related breast cancer

  2002cited by this paper
• Epigenetic factors controlling the BRCA1 and BRCA2 genes in sporadic ovarian cancer.

  2002cited by this paper
• BRCA1 induces DNA damage recognition factors and enhances nucleotide excision repair

  2002cited by this paper
• DNA double strand break repair and chromosomal translocation: Lessons from animal models

  2001cited by this paper
• Inhibition of BRCA1 leads to increased chemoresistance to microtubule-interfering agents, an effect that involves the JNK pathway

  2001cited by this paper
• Role played by BRCA1 in regulating the cellular response to stress.

  2001cited by this paper
• New complexities for BRCA1 and BRCA2.

  2001cited by this paper
• Involvement of Brca1 in S-Phase and G2-Phase Checkpoints after Ionizing Irradiation

  2001cited by this paper
• Antisense inhibition of BRCA1 expression and molecular analysis of hereditary tumors indicate that functional inactivation of the p53 DNA damage response pathway is required for BRCA-associated tumorigenesis.

  2001cited by this paper
• Homology-directed dna repair, mitomycin-c resistance, and chromosome stability is restored with correction of a Brca1 mutation.

  2001cited by this paper
• Functions of BRCA1 and BRCA2 in the biological response to DNA damage.

  2001cited by this paper
• Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer.

  2001cited by this paper
• Prognostic significance of BRCA1 expression in Japanese sporadic breast carcinomas

  2001cited by this paper
• BRCA1 and BRCA2 and the genetics of breast and ovarian cancer.

  2001cited by this paper
• Clinicopathologic features of BRCA-linked and sporadic ovarian cancer.

  2000cited by this paper
• Ovarian carcinoma in situ with germline BRCA1 mutation and loss of heterozygosity at BRCA1 and TP53.

  2000cited by this paper
• Gross chromosomal rearrangements and genetic exchange between nonhomologous chromosomes following BRCA2 inactivation.

  2000cited by this paper
• Chromosome Breaks and Genomic Instability

  2000cited by this paper
• Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors.

  2000cited by this paper
• Acceleration of chromosomal instability by loss of BRCA1 expression and p53 abnormality in sporadic breast cancers.

  2000cited by this paper
• Frequent loss of BRCA1 mRNA and protein expression in sporadic ovarian cancers

  2000cited by this paper
• BASC, a super complex of BRCA1-associated proteins involved in the recognition and repair of aberrant DNA structures.

  2000cited by this paper
• Reduction of BRCA1 expression in sporadic ovarian cancer.

  2000cited by this paper
• The breast surgeon's role in BRCA1 and BRCA2 testing.

  2000cited by this paper
• BRCA1 is associated with a human SWI/SNF-related complex: linking chromatin remodeling to breast cancer.

  2000cited by this paper
• BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study.

  2000cited by this paper
• Loss of heterozygosity (LOH) at p53 is correlated with LOH at BRCA1 and BRCA2 in various human malignant tumors

  2000cited by this paper
• Role of the tumor suppressor gene Brca1 in genetic stability and mammary gland tumor formation

  2000cited by this paper
• Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation

  1999cited by this paper
• Genetic analysis of BRCA1 function in a defined tumor cell line.

  1999cited by this paper
• Requirement of ATM-dependent phosphorylation of brca1 in the DNA damage response to double-strand breaks.

  1999cited by this paper
• Induction of GADD45 and JNK/SAPK-dependent apoptosis following inducible expression of BRCA1.

  1999cited by this paper
• BRCA1 expression levels predict distant metastasis of sporadic breast cancers

  1999cited by this paper
• Ovarian cancer BRCA1 gene therapy: Phase I and II trial differences in immune response and vector stability.

  1999cited by this paper
• Centrosome amplification and a defective G2-M cell cycle checkpoint induce genetic instability in BRCA1 exon 11 isoform-deficient cells.

  1999cited by this paper
• Reduction of BRCA1 protein expression in Japanese sporadic breast carcinomas and its frequent loss in BRCA1-associated cases.

  1999cited by this paper
• BRCA1 regulates p53-dependent gene expression.

  1998cited by this paper
• BRCA1 up-regulation is associated with repair-mediated resistance to cis-diamminedichloroplatinum(II).

  1998cited by this paper
• Frequency of germline and somatic BRCA1 mutations in ovarian cancer.

  1998cited by this paper
• Decreased BRCA1 expression levels may arrest the cell cycle through activation of p53 checkpoint in human sporadic breast tumors.

  1998cited by this paper
• Aberrant methylation of the BRCA1 CpG island promoter is associated with decreased BRCA1 mRNA in sporadic breast cancer cells

  1998cited by this paper
• Molecular genetics of hereditary ovarian cancer.

  1998cited by this paper
• Mutations and alternative splicing of the BRCA1 gene in UK breast/ovarian cancer families

  1997cited by this paper
• BRCA1 is a component of the RNA polymerase II holoenzyme.

  1997cited by this paper
• Partial rescue of Brca15–6 early embryonic lethality by p53 or p21 null mutation

  1997cited by this paper
• How does DNA methylation repress transcription?

  1997cited by this paper
• Arrest of the cell cycle by the tumour-suppressor BRCA1 requires the CDK-inhibitor p21WAF1/CiPl

  1997cited by this paper
• Localization of BRCA1 and a splice variant identifies the nuclear localization signal

  1997cited by this paper
• Dynamic changes of BRCA1 subnuclear location and phosphorylation state are initiated by DNA damage.

  1997cited by this paper
• A phase I trial of retroviral BRCA1sv gene therapy in ovarian cancer.

  1997cited by this paper

• From pathogenesis to management: therapy-related myeloid neoplasms in survivors of female-specific cancers

  2026cites this paper
• Opportunistic salpingectomy for prevention of ovarian cancer among the general population

  2025cites this paper
• Systems biology-driven identification of biomarkers and significant pathways in radiation-induced hormone-sensitive cancers

  2025cites this paper
• Identification of genes predicting chemoresistance and short survival in ovarian cancer

  2024cites this paper
• Spontaneous Transformation of a p53 and Rb-Defective Human Fallopian Tube Epithelial Cell Line after Long Passage with Features of High-Grade Serous Carcinoma

  2022cites this paper
• A bespoke target selection tool to guide biomarker discovery in tubo-ovarian cancer

  2022influential citation
• Liquid biopsy in ovarian cancer: Catching the silent killer before it strikes

  2020cites this paper
• Novel Associations between BRCA1 Variants C.181 T>G (Rs28897672) and Ovarian Crisk in Saudi Females

  2019cites this paper
• Novel treatment options in platinum-sensitive recurrent ovarian cancer: A review.

  2019cites this paper
• Defining the molecular evolution of extrauterine high grade serous carcinoma.

  2019cites this paper
• Exploring the Tumor and Premetastatic Microenvironment of the Ovary

  2019cites this paper
• Translational Research Opportunities Regarding Homologous Recombination in Ovarian Cancer

  2018cites this paper
• Ubiquitin Signaling in Ovarian Cancer: From Potential to Challenges

  2018cites this paper
• Low RAP80 mRNA Expression Correlates with Shorter Survival in Sporadic High-Grade Serous Ovarian Carcinoma

  2017cites this paper
• Epigenetic regulation of BRCA1 expression and its role inbreast cancer stem cell development

  2016cites this paper
• Low-fidelity alternative DNA repair carcinogenesis theory may interpret many cancer features and anticancer strategies.

  2016cites this paper
• Ovarian cancer patients at high risk of BRCA mutation: the constitutional genetic characterization does not change prognosis

  2016cites this paper
• Role of PAX2 in Maintaining the Differentiation of Oviductal Epithelium and Inhibiting the Transition to a Stem Cell State

  2016cites this paper
• The role of Rak in the regulation of stability and function of BRCA1

  2015cites this paper
• Metformin reduces ovarian cancer risk in Taiwanese women with type 2 diabetes mellitus

  2015cites this paper
• miR-185 Suppresses Tumor Proliferation by Directly Targeting E2F6 and DNMT1 and Indirectly Upregulating BRCA1 in Triple-Negative Breast Cancer

  2014cites this paper
• Oncomorphic Tp53 mutations in advanced serous ovarian carcinomas

  2014cites this paper
• Pathway Modulations and Epigenetic Alterations in Ovarian Tumorbiogenesis

  2014cites this paper
• Current Possible Drug Therapies for Ovarian Cancer

  2014cites this paper
• BRCA 1/2-Mutation Related and Sporadic Breast and Ovarian Cancers: More Alike than Different

  2014cites this paper
• Companion Diagnostics and Cancer Biomarkers miR-185 Suppresses Tumor Proliferation by Directly Targeting E 2 F 6 and DNMT 1 and Indirectly Upregulating BRCA 1 in Triple-Negative Breast Cancer

  2014cites this paper
• A New Spontaneously Transformed Syngeneic Model of High-Grade Serous Ovarian Cancer with a Tumor-Initiating Cell Population

  2014cites this paper
• Poly(adenosine diphosphate-ribose) polymerase expression in BRCA-proficient ovarian high-grade serous carcinoma; association with patient survival.

  2013cites this paper
• Timing of Referral for Genetic Counseling and Genetic Testing in Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma

  2013cites this paper
• Pyrimidine base damage is increased in women with BRCA mutations.

  2013cites this paper
• Assessment of the Prognostic Value of Two Common Variants of BRCA1 and BRCA2 Genes in Ovarian Cancer Patients Treated with Cisplatin and Paclitaxel: A Gynecologic Oncology Group Study

  2013cites this paper
• The Role of PARP Inhibitors in the Treatment of Gynecologic Malignancies

  2013cites this paper
• Differing effects of adjuvant chemotherapy according to BRCA1 nuclear expression in gastric cancer

  2013cites this paper
• The Identification and Characterization of Stem/Progenitor Cells in the Ovarian Surface Epithelium

  2013influential citation
• High frequency of allelic loss at the BRCA1 locus in ovarian cancers: clinicopathologic and molecular associations.

  2012cites this paper
• Clinical utility of targeted treatments in the management of epithelial ovarian cancer

  2012cites this paper
• Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer.

  2012cites this paper
• Hereditary ovarian cancer and two-compartment tumor metabolism

  2012cites this paper
• BRCA1 is an essential mediator of vinorelbine‐induced apoptosis in mesothelioma

  2012cites this paper
• Clinical trials and future potential of targeted therapy for ovarian cancer

  2012cites this paper
• BRCA1 protein levels and PIK3CA mutations as predictive biomarkers for response to neoadjuvant chemotherapy in locally advanced breast cancer: An exploratory analysis.

  2012cites this paper
• BRCA1/2 mutations and expression: response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer.

  2012cites this paper
• The ovary feels fine when paracrine and autocrine networks cooperate with gonadotropins in the regulation of folliculogenesis.

  2012cites this paper
• The role of RNA-binding motif 3 in epithelial ovarian cancer: A biomarker discovery approach

  2011influential citation
• Clinical trials and decision-making strategies for optimal treatment of relapsed ovarian cancer.

  2011cites this paper
• Down-regulation of BRCA1 expression by miR-146a and miR-146b-5p in triple negative sporadic breast cancers

  2011cites this paper
• Expression of ERCC1 protein in biopsy specimen predicts survival in advanced ovarian cancer patients treated with platinum-based chemotherapy.

  2011cites this paper
• Intratumoral lymphocyte density in serous ovarian carcinoma is superior to ERCC1 expression for predicting response to platinum-based therapy

  2011cites this paper
• Emerging therapeutic options for platinum-sensitive ovarian cancer patients.

  2011cites this paper
• BRCA Mutation Status and Determinant of Outcome in Women with Recurrent Epithelial Ovarian Cancer Treated with Pegylated Liposomal Doxorubicin

  2011cites this paper
• Clinical Considerations of BRCA1- and BRCA2-Mutation Carriers: A Review

  2011cites this paper
• Molecular Pathology of Ovarian Carcinomas.

  2011cites this paper
• Early oncology clinical trial design in the era of molecular-targeted agents.

  2010cites this paper
• Targeted trials in ovarian cancer.

  2010cites this paper
• Transcriptional Regulation of the Base Excision Repair Pathway by BRCA1*

  2010cites this paper
• Translational research in the Gynecologic Oncology Group: evaluation of ovarian cancer markers, profiles, and novel therapies.

  2010cites this paper
• Status of the BRCA1 gene and incidence of hereditary ovarian cancer

  2010cites this paper
• Upregulation of Poly (ADP-Ribose) Polymerase-1 (PARP1) in Triple-Negative Breast Cancer and Other Primary Human Tumor Types.

  2010cites this paper
• Enhancing the efficacy of platinum-based chemotherapeutics by targeting BRCA1

  2010influential citation
• Optimal treatment for relapsing ovarian cancer.

  2010cites this paper
• BRCA1 as a Therapeutic Target in Sporadic Epithelial Ovarian Cancer

  2010cites this paper
• Cancer esearch cular and Cellular Pathobiology A 1-Associated Epigenetic Regulation of p 73 Mediates an R ctor Pathway for Chemosensitivity in Ovarian Carcinoma

  2010cites this paper
• Fine tuning chemotherapy to match BRCA1 status.

  2010cites this paper
• Mole BRC Effe

  2010cites this paper
• Targeted Therapies in Epithelial Ovarian Cancer

  2010cites this paper
• The mammalian ovary from genesis to revelation.

  2009cites this paper
• Current Opinion in Oncology. Current world literature.

  2009cites this paper
• Biomarker-Driven Early Clinical Trials in Oncology: A Paradigm Shift in Drug Development

  2009cites this paper
• Molecular profiles of hereditary epithelial ovarian cancers and their implications for the biology of this disease

  2009cites this paper
• Proteogenomic studies in epithelial ovarian cancer: established knowledge and future needs.

  2009cites this paper
• The DNA repair proteins BRCA1 and ERCC1 as predictive markers in sporadic ovarian cancer

  2009cites this paper
• BRCA1 and implications for response to chemotherapy in ovarian cancer.

  2009cites this paper
• Research progress in triple-negative breast cancer

  2008cites this paper